Mira PharmaceuticalsMIRA -4.57%13 PB Ratio is 4.10 as of Jun. 25, 2026. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Mira Pharmaceuticals ranks worse than 78.31% on this metric.
The historical rank and industry rank for Mira Pharmaceuticals's PB Ratio or its related term are showing as below:
MIRA'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.39
Current: 4.14
During the past 5 years, Mira Pharmaceuticals's highest PB Ratio was 4.39. The lowest was 0.00. And the median was 0.00.
MIRA's PB Ratio is ranked worse than 78.31% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs MIRA: 4.14
During the past 12 months, Mira Pharmaceuticals's average Book Value Per Share Growth Rate was 86.50% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Mira Pharmaceuticals was -4.60% per year. The lowest was -4.60% per year. And the median was -4.60% per year.
Back to Basics: PB Ratio
Mira Pharmaceuticals (NAS:MIRA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mira Pharmaceuticals PB Ratio Related Terms
Mira Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for Mira Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mira Pharmaceuticals (MIRA) has a PB Ratio of 4.10 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mira Pharmaceuticals and its competitors. According to the industry distribution chart, Mira Pharmaceuticals ranks #722 out of 922 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Mira Pharmaceuticals' PB Ratio too high?
Mira Pharmaceuticals' current PB Ratio is 4.10. The Drug Manufacturers industry median PB Ratio is 1.86. Mira Pharmaceuticals' value of 4.10 is 121% above this industry median. Based on the distribution chart, Mira Pharmaceuticals ranks #722 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' PB Ratio compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #722 out of 922 companies for PB Ratio. This places Mira Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.86. Mira Pharmaceuticals' value of 4.10 is 121% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mira Pharmaceuticals's current PB Ratio of 4.10 is 121% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mira Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mira Pharmaceuticals's current PB Ratio is 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current PB Ratio of 4.10. The current PB Ratio is 4.10 and 121% above the Drug Manufacturers industry median of 1.86. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current PB Ratio is 4.10 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score
Get the complete analysis for MIRA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRA has been successfully added to your 
